Earnings ·
Insulet reports Q3 revenue of $842 million, up 19.2%, and authorizes $1 billion share buyback
PODDInsulet Corp
Insulet Corporation announced third-quarter financial results for the period ended September 30, 2026, reporting total revenue of $842.0 million, a 19.2% increase from the prior year. Net income rose to $141.1 million, or $2.03 per diluted share, compared to $87.6 million in the previous year. The company also disclosed that its Board of Directors authorized a new stock repurchase program allowing for up to $1 billion in buybacks through December 31, 2028, with approximately $400 million allocated for the fourth quarter of 2026. Insulet Corporation is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform.